Repligen Corporation
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression (NCT00812058) | Repligen Corporation | 2008-11-01 |
| Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas (NCT00660335) | Repligen Corporation | 2008-03-01 |
| Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression (NCT00322764) | Repligen Corporation | 2006-03-01 |
| Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction (NCT00036231) | Repligen Corporation | 2002-04-01 |
| Synthetic Human Secretin in Children With Autism (NCT00036244) | Repligen Corporation | 2002-04-01 |
| RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease (NCT00060515) | Repligen Corporation |
Track Repligen Corporation automatically
Every clearance here is in the API, with alerts when new ones post.